| 产品名称 | Vandetanib - ZD 6474 |
| 产品货号 | Axon 1411 CAS [443913-73-3] MF C22H24BrFN4O2MW 475.35 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description An orally bioavailable tyrosine kinase inhibitor (TKI), targeting VEGFR, EGFR, and RET; a potential medication for non-small-cell lung cancer. References Certificates Categories Extra info RS Herbst et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin. Investig. Drugs. 2007, 16, 239-249. SR Wedge et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62, 4645-4655. D. Vitagliano et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer. 2010 Nov 30;18(1):1-11. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology EGFR VEGFR JAK-STAT RTK class I and IV; EC 2.7.10.1 VEGFR and EGFR tyrosine kinase inhibitor Chemical name (4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine Parent CAS No. [443913-73-3] Order Size Unit Price Stock 5 mg €55.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
Vandetanib - ZD 6474Axon 1411 CAS [443913-73-3] MF C22H24BrFN4O2
Description
An orally bioavailable tyrosine kinase inhibitor (TKI), targeting VEGFR, EGFR, and RET; a potential medication for non-small-cell lung cancer.
VEGFR and EGFR tyrosine kinase inhibitor
Chemical name(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine Parent CAS No.[443913-73-3] |
| 产品资料 |
